

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Novalis LifeSciences Investments II GP, LLC</u>  (Last) (First) (Middle) 1 LIBERTY LANE E, SUITE 112  (Street) HAMPTON NH 03842  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/05/2023	3. Issuer Name and Ticker or Trading Symbol <u>Telesis Bio Inc. [ TBIO ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	6,558,625 <sup>(1)</sup>	2.3633	I	See footnotes <sup>(3)</sup> <sup>(4)</sup>
Warrant (right to buy)	06/05/2023	06/05/2030	Common Stock	6,558,626 <sup>(2)</sup>	2.5996	I	See footnotes <sup>(3)</sup> <sup>(4)</sup>
Warrant (right to buy)	06/05/2023	06/05/2025	Common Stock	3,279,313 <sup>(2)</sup>	2.5996	I	See footnotes <sup>(3)</sup> <sup>(4)</sup>

1. Name and Address of Reporting Person* <u>Novalis LifeSciences Investments II GP, LLC</u>  (Last) (First) (Middle) 1 LIBERTY LANE E, SUITE 112  (Street) HAMPTON NH 03842  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Novalis LifeSciences Investments II, L.P.</u>  (Last) (First) (Middle) 1 LIBERTY LANE E, SUITE 112  (Street) HAMPTON NH 03842		
--	--	--

